课题基金 / 基金详情

项目摘要

项目成果

Stephen J Forman的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The ISCT annual meeting is the premier opportunity for those working or interested in cell based therapeutic development to exchange scientific, clinical, technical, commercial, and regulatory information with colleagues from academia, industry, and regulatory agencies around the world. Last year's conference welcomed over 660 delegates from all over the world. We expect a modest increase again this year and are planning to host over 700 people. To enhance our program, we are adding an interactive Public Session aimed at encouraging high school and college students to pursue careers as researchers and physicians in the area of cellular therapy. The chairs of this meeting are Dr. Steven Forman, Clinical Director, Division of Cancer Immunotherapeutics and Tumor Immunology, City of Hope and Dr. Bruce Torbett, Associate Professor, Department of Molecular and Experimental Medicine, Scripps Research Institute. Program Objectives The objectives of the ISCT annual meeting include: (a) emphasizing the translational aspects of and issues involved with all types of cell and tissue-based research (b) Encouraging cross-disciplinary participation in Society activities (e.g., membership, publications, educational programs, conferences, etc) from scientists, clinicians, laboratory personnel, regulatory professionals, and others from both academia and industry (c) Addressing the scientific, clinical, laboratory and regulatory issues related to each type of cell-based research/therapy (d) facilitating the translation of information and experience from more mature cellular research areas such as hematopoietic stem cell transplantation to other emerging areas including nonhematopoietic areas such as mesenchymal stem cells, islet cells, etc and (d) Facilitating the transfer of information and experience from senior practicioners to young scientists in the field. (End of Abstract)
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Intracerebroventricular (ICV) Administration of CD19-Targeting Chimeric Antigen Receptor (CAR) T cells for Treatment of Primary Central Nervous System Lymphoma
Intracerebroventricular (ICV) Administration of CD19-Targeting Chimeric Antigen Receptor (CAR) T cells for Treatment of Primary Central Nervous System Lymphoma
Transfer of COVID-19 Immunity Between
Image-guided irradiation safely intensifies HSCT regimen for refractory leukemia
海外基金